A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature research

2025/12/10 by Amaral, Teresa, Nanz, Lena, Higuita, Lina Maria Serna +19
#610 Medicine &amp #Adjuvant therapy #Checkpoint inhibitors #Distant metastasis-free survival #Overall survival #Relapse-free survival #Stage III #Targeted therapy #health

paper · doi:10.5167/uzh-280414

Abstract

Real-world data suggest that adjuvant TT may be associated with better RFS and DMFS in stage III BRAF V600-mutated melanoma compared to ICI.

Related

• Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma
• Switching PD-1 to BRAF + MEK inhibition improves recurrence-free survival in patients receiving a second course of adjuvant melanoma therapy
• A plain language summary of the 7-year update from part 1 of the COLUMBUS study: encorafenib and binimetinib for people with BRAF V600-mutant melanoma
• Analysis of BRAF mutations in circulating tumor cells selected by size from patients with melanoma and comparision to the primary tumor.
• Le gène BRAF : un marqueur prédictif des mélanomes conjonctivaux